Author

H. Hirano

h-index 15 View on Semantic Scholar

We have 3 of 145 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

BACKGROUND The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/...

H. Hirano, Yasuhide Yamada, Kengo Nagashima et al. · British Journal of Cancer · 0 citations

Open access Sep 2026

A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).

BACKGROUND There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who expe...

Toshifumi Yamaguchi, R. Kawabata, Y. Akamaru et al. · Gastric Cancer · 0 citations

Open access Aug 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC and proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.

Shohei Udagawa, Chihiro Ishizuka, H. Osumi et al. · International Journal of Cli... · 0 citations